Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0268596 (EMA)
 2,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Using allelochemicals produced by macrophytes to control harmful algae is a novel antialgal method. The present research investigated effects of the species-specific antialgal allelochemical EMA on activities of antioxidant enzymes of Chlorella pyrenoidosa and Chlorella vulagaris. The results showed that 0.25 mg/L of EMA increased activities of superoxide dismutase (SOD), peroxidase (POD)and catalase (CAT) of C. pyrenoidosa and C. vulagaris. With the increase of EMA concentrations, activities of the 3 enzymes of C. pyrenoidosa decreased sharply. The activity of SOD of C. pyrenoidosa decreased to 0 when the EMA were 4 mg/L. With the increase of EMA concentrations, activities of the 3 enzymes of C. vulagaris increased to as higher as 3-4 folders of that of the control set. The results gave hints to elucidate the species-specific antialgal mechanisms of EMA.
 ...
PMID:[Effects of EMA on activities of algal antioxidant enzymes]. 1725 16

Hematopoiesis as the only essential function of bone marrow cells has been challenged for several decades through basic science (in vitro and in vivo) and clinical data. Such work has shed light on two other essential functions of bone marrow cells: osteopoiesis and angio-genesis/vasculogenesis. Clinical utility of autologous concentrated bone marrow aspirate (CBMA) has demonstrated both safety and efficacy in treating bone defects. Moreover, CBMA has been shown to be comparable to the gold standard of iliac crest bone graft (ICBG), or autograft, with regard to being osteogenic and osteoinductive. ICBG is not considered an advanced therapy medicinal product (ATMP), but CBMA may become regulated as an ATMP. The European Medicines Agency Committee for Advanced Therapies (EMA:CAT) has issued a reflection paper (20 June 2014) in which reversal of the 2013 ruling that CBMA is a non-ATMP has been proposed. We review bone marrow cell involvement in osteopoiesis and angiogenesis/vasculogenesis to examine EMA:CAT 2013 decision to use CBMA for treatment of osteonecrosis (e.g, of the femoral head) should be considered a non-ATMP. This paper is intended to provide discussion on the 20 June 2014 reflection paper by reviewing two non-hematopoietic essential functions of bone marrow cells. Additionally, we provide clinical and scientific rationale for treating osteonecrosis with CBMA.
...
PMID:Non-Hematopoietic Essential Functions of Bone Marrow Cells: A Review of Scientific and Clinical Literature and Rationale for Treating Bone Defects. 2679 90